申请人:Richter Gedeon Vegyeszeti Gyar Rt.
公开号:US04057551A1
公开(公告)日:1977-11-08
New compounds of the general formula (I) ##STR1## wherein R stands for an alkyl group, have been prepared by reducing a compound of the general formula (II) ##STR2## wherein R stands for alkyl, B stands for H.sub.2 O or an X.sup.- anion derived from an acid, and if B is an X.sup.- anion, A represents hydrogen, whereas if B is H.sub.2 O, A represents an electron pair. If desired, the racemic compounds of the general formula (I) can be resolved to yield the corresponding optically active isomers. The free bases of the general formula (I) can be converted into their pharmaceutically acceptable salts, or the salts can be treated with an alkaline agent to yield the free bases. The compounds of the general formula (I) can be used in the therapy primarily as vasodilatating agents.
通式为(I)的新化合物已经通过还原通式为(II)的化合物制备而成,其中R代表烷基。在通式(II)中,R代表烷基,B代表H2O或从酸中得到的X-阴离子。如果B是X-阴离子,则A代表氢,而如果B是H2O,则A代表电子对。如果需要,通式(I)的外消旋化合物可以被分离成相应的光学活性异构体。通式(I)的自由碱可以转化为其药学上可接受的盐,或者可以用碱性试剂处理盐以得到自由碱。通式(I)的化合物可以作为血管扩张剂在治疗中使用。